SMC Scottish Medicines Consortium
Advising on new medicines for Scotland
www.scottishmedicines.org.uk
Delta House • 50 West Nile Street • Glasgow • G1 2NP • Tel 0141 225 6999 • Chairman: Dr Alan G MacDonald
NHS SCOTLAND

Product Update:

darunavir 800mg, cobicistat 150mg, emtricitabine 200mg, tenofovir alafenamide 10mg film-coated tablet (Symtuza®) SMC No 1290/18
Janssen-Cilag Ltd

8 December 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

darunavir, cobicistat, emtricitabine, tenofovir alafenamide (Symtuza®) is accepted for use within NHS Scotland.

Indication under review: the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).

SMC has previously accepted darunavir/cobicistat (Rezolsta®) and emtrictabine/tenofovir alafenamide (Descovy®). Symtuza® (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) provides a single-tablet alternative to Rezolsta® plus Descovy® at no additional cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including ***16 October 2017.***

Chairman
Scottish Medicines Consortium

Published 15 January 2018